论文部分内容阅读
目的探讨肝细胞性肝癌（ＨＣＣ）组织中转化生长因子β２（ＴＧＦβ２）的表达及其临床病理学意义。方法ＡＢＣ免疫组化方法检测５２例我所１９９２～１９９５年手术切除的小肝癌中ＴＧＦβ２的免疫反应性，并根据术后２年内肝癌有无复发，将５２例小肝癌分为复发组和无复发组。分析其临床病理学意义。结果有门脉癌栓者，术后２年复发率为８２４％（１４／１７），无门脉癌栓者，术后２年复发率为１７１％（６／３５），两者统计学上有显著性差异（Ｐ＜００５）。复发组ＴＧＦβ２强阳性率４００％（８／２０），无复发组ＴＧＦβ２强阳性率１２５％（４／３２），统计学上两组之间差异有显著性（Ｐ＜００５）。有门脉癌栓者，ＴＧＦβ２强阳性率４７１％（８／１７），无门脉癌栓者，ＴＧＦβ２强阳性率１１４％（４／３５），两者之间统计学上有显著性差异。结论ＴＧＦβ２的表达异常与肝癌复发、门脉癌栓正相关
Objective To investigate the expression of transforming growth factor-β2 (TGFβ2) in hepatocellular carcinoma (HCC) and its clinicopathological significance. Methods ABC immunohistochemical method was used to detect the immunoreactivity of TGFβ2 in 52 cases of small hepatic carcinoma surgically resected from 1992 to 1995. According to the recurrence of liver cancer within 2 years after operation, 52 cases of small hepatocarcinoma were divided into relapsed group and no recurrence. group. Analyze its clinical pathological significance. Results The patients with portal vein cancer thrombosis had a recurrence rate of 82.4% (14/17) at 2 years after operation. Without portal vein cancer thrombosis, the recurrence rate was 17.1% (6/35) at 2 years after operation. There was a statistically significant difference (P<005). The positive rate of TGFβ2 in the relapse group was 40.0% (8/20), and the strong positive rate of TGFβ2 in the non-relapse group was 12.5% (4/32). There was a statistically significant difference between the two groups (P<005). ). In portal vein tumor thromboses, the strong positive rate of TGFβ2 was 47.1% (8/17). Without portal vein tumor thrombosis, the strong positive rate of TGFβ2 was 11.4% (4/35). There was a statistically significant difference between them. Significant difference. Conclusion The abnormal expression of TGFβ2 is positively correlated with the recurrence of HCC and portal vein cancer thrombus.